Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1994 1
1995 1
1996 3
1997 3
1998 4
1999 14
2000 19
2001 23
2002 17
2003 23
2004 18
2005 33
2006 62
2007 52
2008 42
2009 43
2010 42
2011 36
2012 52
2013 45
2014 40
2015 54
2016 51
2017 51
2018 53
2019 56
2020 85
2021 96
2022 35
Text availability
Article attribute
Article type
Publication date

Search Results

954 results
Results by year
Filters applied: . Clear all
Page 1
Oncolytic herpes simplex virus and immunotherapy.
Ma W, He H, Wang H. Ma W, et al. BMC Immunol. 2018 Dec 18;19(1):40. doi: 10.1186/s12865-018-0281-9. BMC Immunol. 2018. PMID: 30563466 Free PMC article. Review.
BACKGROUND: Oncolytic viruses have been proposed to be employed as a potential treatment of cancer. Well targeted, they will serve the purpose of cracking tumor cells without causing damage to normal cells. In this category of oncolytic viral drugs human pathogens …
BACKGROUND: Oncolytic viruses have been proposed to be employed as a potential treatment of cancer. Well targeted, they will serve th …
Oncolytic Herpes Simplex Virus-Based Therapies for Cancer.
Aldrak N, Alsaab S, Algethami A, Bhere D, Wakimoto H, Shah K, Alomary MN, Zaidan N. Aldrak N, et al. Cells. 2021 Jun 18;10(6):1541. doi: 10.3390/cells10061541. Cells. 2021. PMID: 34207386 Free PMC article. Review.
With the increased worldwide burden of cancer, including aggressive and resistant cancers, oncolytic virotherapy has emerged as a viable therapeutic option. Oncolytic herpes simplex virus (oHSV) can be genetically engineered to target cancer cells whil …
With the increased worldwide burden of cancer, including aggressive and resistant cancers, oncolytic virotherapy has emerged as a via …
Recent advances of oncolytic virus in cancer therapy.
Mondal M, Guo J, He P, Zhou D. Mondal M, et al. Hum Vaccin Immunother. 2020 Oct 2;16(10):2389-2402. doi: 10.1080/21645515.2020.1723363. Epub 2020 Feb 20. Hum Vaccin Immunother. 2020. PMID: 32078405 Free PMC article. Review.
Oncolytic viruses have been taking the front stage in biological therapy for cancer recently. The first and most potent virus to be used in oncolytic virotherapy is human adenovirus. Recently, ongoing extensive research has suggested that other viruses like herpe
Oncolytic viruses have been taking the front stage in biological therapy for cancer recently. The first and most potent virus to be u
Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy.
Menotti L, Avitabile E. Menotti L, et al. Int J Mol Sci. 2020 Nov 5;21(21):8310. doi: 10.3390/ijms21218310. Int J Mol Sci. 2020. PMID: 33167582 Free PMC article. Review.
Oncolytic virotherapy strategies based on the herpes simplex virus are reaching their thirties, and a wide variety of approaches has been envisioned and tested in many different models, and on a range of tumor targets. This huge effort has culminated in the p
Oncolytic virotherapy strategies based on the herpes simplex virus are reaching their thirties, and a wide variety of a
Oncolytic Herpes Simplex Virus Vectors Fully Retargeted to Tumor- Associated Antigens.
Uchida H, Hamada H, Nakano K, Kwon H, Tahara H, Cohen JB, Glorioso JC. Uchida H, et al. Curr Cancer Drug Targets. 2018;18(2):162-170. doi: 10.2174/1568009617666170206105855. Curr Cancer Drug Targets. 2018. PMID: 28176649 Review.
Oncolytic virotherapy is a novel therapeutic modality for malignant diseases that exploits selective viral replication in cancer cells. Herpes simplex virus (HSV) is a promising agent for oncolytic virotherapy due to its broad cell tropism and the iden
Oncolytic virotherapy is a novel therapeutic modality for malignant diseases that exploits selective viral replication in cancer cell
Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells.
Sanchala DS, Bhatt LK, Prabhavalkar KS. Sanchala DS, et al. Front Pharmacol. 2017 May 16;8:270. doi: 10.3389/fphar.2017.00270. eCollection 2017. Front Pharmacol. 2017. PMID: 28559846 Free PMC article. Review.
This review provides an exhaustive list of oncolytic herpes simplex virus-1 along with their genetic alterations. It also encompasses the major developments in oncolytic herpes simplex-1 viral therapy and outlines the limitations and draw …
This review provides an exhaustive list of oncolytic herpes simplex virus-1 along with their genetic alterations. It al …
Oncolytic herpes simplex virus therapy for malignant glioma: current approaches to successful clinical application.
Hua L, Wakimoto H. Hua L, et al. Expert Opin Biol Ther. 2019 Aug;19(8):845-854. doi: 10.1080/14712598.2019.1614557. Epub 2019 May 13. Expert Opin Biol Ther. 2019. PMID: 31046478 Review.
INTRODUCTION: With the approval of talimogene laherparepvec (T-VEC) for advanced malignant melanoma, virotherapy using oncolytic herpes simplex virus (oHSV) is now emerging as a viable therapeutic option for cancer patients, including malignant gliomas. ...
INTRODUCTION: With the approval of talimogene laherparepvec (T-VEC) for advanced malignant melanoma, virotherapy using oncolytic h
Oncolytic virus therapy: A new era of cancer treatment at dawn.
Fukuhara H, Ino Y, Todo T. Fukuhara H, et al. Cancer Sci. 2016 Oct;107(10):1373-1379. doi: 10.1111/cas.13027. Epub 2016 Sep 9. Cancer Sci. 2016. PMID: 27486853 Free PMC article. Review.
T-Vec (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1 (HSV-1) armed with GM-CSF, was recently approved as the first oncolytic virus drug in the USA and Europe. ...It appears that it will not be long before oncol
T-Vec (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1 (HSV-1) armed with GM-CSF, …
Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
Thomas S, Kuncheria L, Roulstone V, Kyula JN, Mansfield D, Bommareddy PK, Smith H, Kaufman HL, Harrington KJ, Coffin RS. Thomas S, et al. J Immunother Cancer. 2019 Aug 10;7(1):214. doi: 10.1186/s40425-019-0682-1. J Immunother Cancer. 2019. PMID: 31399043 Free PMC article.
Finally, HSV-1 has a proven safety and efficacy profile in patients with cancer, talimogene laherparepvec (T-VEC), an oncolytic HSV-1 which expresses GM-CSF, being the only oncolytic immunotherapy approach that has received FDA approval. As the clinical efficacy of …
Finally, HSV-1 has a proven safety and efficacy profile in patients with cancer, talimogene laherparepvec (T-VEC), an oncolytic HSV-1 …
The Current State of Oncolytic Herpes Simplex Virus for Glioblastoma Treatment.
Nguyen HM, Saha D. Nguyen HM, et al. Oncolytic Virother. 2021 Feb 24;10:1-27. doi: 10.2147/OV.S268426. eCollection 2021. Oncolytic Virother. 2021. PMID: 33659221 Free PMC article. Review.
The recent emergence of immuno-virotherapy and FDA approval of T-VEC have generated a great expectation towards oncolytic herpes simplex viruses (oHSVs) as a promising treatment option for GBM. ...
The recent emergence of immuno-virotherapy and FDA approval of T-VEC have generated a great expectation towards oncolytic herpes
954 results